Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Narayana Hrudayalaya Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹1,812.00
High
₹1,854.00
Price Summary
| Previous Close | ₹1,847.50 |
|---|---|
| Day's Range | ₹1,812.00 - ₹1,854.00 |
| Open | ₹1,827.40 |
| 52 Week Range | ₹1,589.00 - ₹2,370.20 |
| Volume | 1,50,159 |
| Market Cap | ₹0.04 |
| Previous Close | ₹1,846.00 |
|---|---|
| Day's Range | ₹1,811.40 - ₹1,852.40 |
| Open | ₹1,829.95 |
| 52 Week Range | ₹1,564.25 - ₹2,371.60 |
| Volume | 4,040 |
| Market Cap | ₹0.04 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 2,774.19 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.25 |
| Price/Earning (TTM) | 47.61 |
| TTM EPS (₹) | 38.12 |
| P/E Ratio | 43.74 |
| Book Value(₹) | 8.85 |
| PAT Margin (%) | 14.40 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 21.62 |
| Trade Value ( ₹ in Lacs) | 74.58 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.25 |
| Price/Earning (TTM) | 47.61 |
| TTM EPS (₹) | 38.12 |
| P/E Ratio | 43.74 |
| Book Value(₹) | 8.85 |
| PAT Margin (%) | 14.40 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 21.62 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 8650.43 | 48902.07 |
| Expenses | N/A | N/A |
| PBT | 1014.44 | 8839.93 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 792.23 | 7896.24 |
About Narayana Hrudayalaya Ltd.
| Founded | 2000 |
|---|---|
| Managing Director | Emmanuel Rupert |
| NSE Symbol | NH |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,47,032.09 | 1,877.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,83,758.68 | 6,826.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,223.98 | 4,418.55 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,692.75 | 8,077.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,214.23 | 1,435.35 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,08,739.11 | 1,317.60 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,230.20 | 2,277.45 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,02,166.27 | 1,052.35 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,01,634.21 | 2,506.00 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 99,747.98 | 1,013.50 | 835.50 - 835.50 |
No Records Found
Latest News
May
15
2026
Posted on May 15th 2026
Akums Drugs & Pharma - Quaterly Results
The total revenue for the quarter ended March 2026 remained nearly unchanged at Rs. 3383.72 millions.Profit after Tax for the quarter ended March 2026 saw a decline of -44.92% from Rs. 275.89 millions to Rs. 151.97 millions.The company reported a degrowth in operating Profit to 395.16 millions from 497.74 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 3383.72 | 3287.53 | 2.93 | 13487.36 | 13117.84 | 2.82 | 13487.36 | 13117.84 | 2.82 |
| Other Income | 277.29 | 320.50 | -13.48 | 1129.65 | 1241.92 | -9.04 | 1129.65 | 1241.92 | -9.04 |
| PBIDT | 395.16 | 497.74 | -20.61 | 2104.25 | 2626.91 | -19.90 | 2104.25 | 2626.91 | -19.90 |
| Interest | 25.93 | 26.26 | -1.26 | 100.38 | 153.09 | -34.43 | 100.38 | 153.09 | -34.43 |
| PBDT | 342.12 | 471.48 | -27.44 | 1938.68 | 2473.82 | -21.63 | 1938.68 | 2473.82 | -21.63 |
| Depreciation | 124.21 | 100.93 | 23.07 | 455.03 | 395.45 | 15.07 | 455.03 | 395.45 | 15.07 |
| PBT | 217.91 | 370.55 | -41.19 | 1483.65 | 2078.37 | -28.61 | 1483.65 | 2078.37 | -28.61 |
| TAX | 65.94 | 94.66 | -30.34 | 367.25 | 468.39 | -21.59 | 367.25 | 468.39 | -21.59 |
| Deferred Tax | 33.28 | 12.05 | 176.18 | -3.69 | -7.14 | -48.32 | -3.69 | -7.14 | -48.32 |
| PAT | 151.97 | 275.89 | -44.92 | 1116.40 | 1609.98 | -30.66 | 1116.40 | 1609.98 | -30.66 |
| Equity | 306.21 | 306.21 | 0.00 | 306.21 | 306.21 | 0.00 | 306.21 | 306.21 | 0.00 |
| PBIDTM(%) | 11.68 | 15.14 | -22.87 | 15.60 | 20.03 | -22.09 | 15.60 | 20.03 | -22.09 |
Read More
May
15
2026
Posted on May 15th 2026
Global Health - Quaterly Results
The revenue for the March 2026 quarter is pegged at Rs. 9606.29 millions, about 19.65% up against Rs. 8028.68 millions recorded during the year-ago period.A comparatively good net profit growth of 32.89% to Rs. 1241.31 millions was reported for the quarter ended March 2026 compared to Rs. 934.12 millions of previous same quarter.Operating profit surged to 2291.47 millions from the corresponding previous quarter of 2208.62 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 9606.29 | 8028.68 | 19.65 | 37093.78 | 32041.46 | 15.77 | 37093.78 | 32041.46 | 15.77 |
| Other Income | 358.05 | 256.66 | 39.50 | 1064.08 | 908.09 | 17.18 | 1064.08 | 908.09 | 17.18 |
| PBIDT | 2291.47 | 2208.62 | 3.75 | 8612.69 | 8559.45 | 0.62 | 8612.69 | 8559.45 | 0.62 |
| Interest | 134.64 | 70.99 | 89.66 | 410.85 | 333.91 | 23.04 | 410.85 | 333.91 | 23.04 |
| PBDT | 2156.83 | 1638.67 | 31.62 | 8205.61 | 7726.58 | 6.20 | 8205.61 | 7726.58 | 6.20 |
| Depreciation | 522.08 | 379.80 | 37.46 | 1709.07 | 1496.11 | 14.23 | 1709.07 | 1496.11 | 14.23 |
| PBT | 1634.75 | 1258.87 | 29.86 | 6496.54 | 6230.47 | 4.27 | 6496.54 | 6230.47 | 4.27 |
| TAX | 393.44 | 324.75 | 21.15 | 1534.53 | 1615.19 | -4.99 | 1534.53 | 1615.19 | -4.99 |
| Deferred Tax | 74.98 | -43.90 | -270.80 | 222.11 | -0.34 | -65426.47 | 222.11 | -0.34 | -65426.47 |
| PAT | 1241.31 | 934.12 | 32.89 | 4962.01 | 4615.28 | 7.51 | 4962.01 | 4615.28 | 7.51 |
| Equity | 537.38 | 537.17 | 0.04 | 537.38 | 537.17 | 0.04 | 537.38 | 537.17 | 0.04 |
| PBIDTM(%) | 23.85 | 27.51 | -13.29 | 23.22 | 26.71 | -13.08 | 23.22 | 26.71 | -13.08 |
Read More
May
15
2026
Posted on May 15th 2026
Caplin Point Lab - Quaterly Results
The company witnessed a 10.22% growth in the revenue at Rs. 1913.60 millions for the quarter ended March 2026 as compared to Rs. 1736.10 millions during the year-ago period.A good growth in profit of 26.59% reported to Rs. 1095.00 millions over Rs. 865.00 millions of corresponding previous quarter.The company reported a good operating profit of 1446.70 millions compared to 1162.90 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 1913.60 | 1736.10 | 10.22 | 7383.30 | 7524.10 | -1.87 | 7383.30 | 7524.10 | -1.87 |
| Other Income | 610.80 | 412.50 | 48.07 | 1953.70 | 1345.90 | 45.16 | 1953.70 | 1345.90 | 45.16 |
| PBIDT | 1446.70 | 1162.90 | 24.40 | 5331.50 | 4665.60 | 14.27 | 5331.50 | 4665.60 | 14.27 |
| Interest | 0.50 | 0.40 | 25.00 | 2.00 | 1.20 | 66.67 | 2.00 | 1.20 | 66.67 |
| PBDT | 1446.20 | 1162.50 | 24.40 | 5329.50 | 4664.40 | 14.26 | 5329.50 | 4664.40 | 14.26 |
| Depreciation | 69.00 | 60.90 | 13.30 | 254.30 | 247.70 | 2.66 | 254.30 | 247.70 | 2.66 |
| PBT | 1377.20 | 1101.60 | 25.02 | 5075.20 | 4416.70 | 14.91 | 5075.20 | 4416.70 | 14.91 |
| TAX | 282.20 | 236.60 | 19.27 | 1109.40 | 1021.80 | 8.57 | 1109.40 | 1021.80 | 8.57 |
| Deferred Tax | 17.70 | 0.30 | 5800.00 | 14.50 | -7.20 | -301.39 | 14.50 | -7.20 | -301.39 |
| PAT | 1095.00 | 865.00 | 26.59 | 3965.80 | 3394.90 | 16.82 | 3965.80 | 3394.90 | 16.82 |
| Equity | 152.00 | 152.00 | 0.00 | 152.00 | 152.00 | 0.00 | 152.00 | 152.00 | 0.00 |
| PBIDTM(%) | 75.60 | 66.98 | 12.87 | 72.21 | 62.01 | 16.45 | 72.21 | 62.01 | 16.45 |
Read More
May
15
2026
Posted on May 15th 2026
Shree Ganesh Remed. - Quaterly Results
The sales surged to Rs. 331.96 millions, up 35.87% for the March 2026 quarter as against Rs. 244.32 millions during the corresponding quarter previous year.The Net Profit of the company registered a slight decline of -4.91% to Rs. 62.73 millions from Rs. 65.97 millions.OP of the company witnessed a marginal growth to 123.98 millions from 121.63 millions in the same quarter last year.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 331.96 | 244.32 | 35.87 | 1092.86 | 1085.96 | 0.64 | 1092.86 | 1085.96 | 0.64 |
| Other Income | 10.23 | 22.87 | -55.27 | 30.30 | 37.30 | -18.77 | 30.30 | 37.30 | -18.77 |
| PBIDT | 123.98 | 121.63 | 1.93 | 380.50 | 429.42 | -11.39 | 380.50 | 429.42 | -11.39 |
| Interest | 8.76 | 9.58 | -8.56 | 35.62 | 20.77 | 71.50 | 35.62 | 20.77 | 71.50 |
| PBDT | 115.22 | 112.05 | 2.83 | 344.88 | 408.65 | -15.61 | 344.88 | 408.65 | -15.61 |
| Depreciation | 27.98 | 24.24 | 15.43 | 104.73 | 95.67 | 9.47 | 104.73 | 95.67 | 9.47 |
| PBT | 87.24 | 87.81 | -0.65 | 240.15 | 312.98 | -23.27 | 240.15 | 312.98 | -23.27 |
| TAX | 24.51 | 21.84 | 12.23 | 62.42 | 81.99 | -23.87 | 62.42 | 81.99 | -23.87 |
| Deferred Tax | 9.78 | -0.81 | -1307.41 | 5.33 | -0.45 | -1284.44 | 5.33 | -0.45 | -1284.44 |
| PAT | 62.73 | 65.97 | -4.91 | 177.73 | 230.99 | -23.06 | 177.73 | 230.99 | -23.06 |
| Equity | 128.38 | 128.38 | 0.00 | 128.38 | 128.38 | 0.00 | 128.38 | 128.38 | 0.00 |
| PBIDTM(%) | 37.35 | 49.78 | -24.98 | 34.82 | 39.54 | -11.95 | 34.82 | 39.54 | -11.95 |
Read More
May
15
2026
Posted on May 15th 2026
Senores Pharmaceutic - Quaterly Results
The total revenue surged to Rs. 368.10 millions, up 210.37% for the March 2026 quarter as against Rs. 118.60 millions during the year-ago period.The company almost doubled its revenue to Rs. 84.80 millions from Rs. 20.20 millions in the quarter ended March 2026.The company reported a good operating profit of 187.10 millions compared to 65.20 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 368.10 | 118.60 | 210.37 | 1060.90 | 385.40 | 175.27 | 1060.90 | 385.40 | 175.27 |
| Other Income | 221.90 | 92.50 | 139.89 | 663.50 | 219.90 | 201.73 | 663.50 | 219.90 | 201.73 |
| PBIDT | 187.10 | 65.20 | 186.96 | 476.70 | 147.10 | 224.07 | 476.70 | 147.10 | 224.07 |
| Interest | 18.90 | 23.50 | -19.57 | 69.80 | 65.20 | 7.06 | 69.80 | 65.20 | 7.06 |
| PBDT | 168.20 | 41.70 | 303.36 | 406.90 | 81.90 | 396.83 | 406.90 | 81.90 | 396.83 |
| Depreciation | 41.30 | 12.70 | 225.20 | 132.30 | 30.80 | 329.55 | 132.30 | 30.80 | 329.55 |
| PBT | 126.90 | 29.00 | 337.59 | 274.60 | 51.10 | 437.38 | 274.60 | 51.10 | 437.38 |
| TAX | 42.10 | 8.80 | 378.41 | 72.10 | 14.20 | 407.75 | 72.10 | 14.20 | 407.75 |
| Deferred Tax | -22.70 | 4.00 | -667.50 | -12.40 | -0.30 | 4033.33 | -12.40 | -0.30 | 4033.33 |
| PAT | 84.80 | 20.20 | 319.80 | 202.50 | 36.90 | 448.78 | 202.50 | 36.90 | 448.78 |
| Equity | 460.50 | 460.50 | 0.00 | 460.50 | 460.50 | 0.00 | 460.50 | 460.50 | 0.00 |
| PBIDTM(%) | 50.83 | 54.97 | -7.54 | 44.93 | 38.17 | 17.73 | 44.93 | 38.17 | 17.73 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Narayana Hrudayalaya Ltd. is ₹1,847.50 as of 2026-05-15.
The market capitalisation of Narayana Hrudayalaya Ltd. is ₹37,084.33 as of 2026-05-14.
The 1-year return of Narayana Hrudayalaya Ltd. is 28.10% as of 2026-05-15.
The P/E ratio of Narayana Hrudayalaya Ltd. is 43.74 as of 2026-05-15.
The 52-week high and low of Narayana Hrudayalaya Ltd. are ₹2,370.20 and ₹1,589.00, respectively, as of 2026-05-15.
View More
People Also Ask
Narayana Hrudayalaya Ltd. establishes partnerships by collaborating with regional governments to operate specialised public-private healthcare facilities. The hospital chain also works closely with medical technology firms to implement advanced, cost-effective surgical equipment across its network.
Narayana Hrudayalaya Ltd. provides extensive multi-specialty healthcare facilities, operating a network of over 40 hospitals and primary care clinics. The enterprise is globally ren
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
